| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 202,510 | 176,306 | ||
| Marketable debt securities | 222,738 | 311,279 | ||
| Accounts receivable, net | 112,543 | 124,464 | ||
| Inventory | 52,200 | 46,498 | ||
| Prepaid expenses and other assets | 53,215 | 61,241 | ||
| Total current assets | 643,206 | 719,788 | ||
| Property, plant, and equipment, net | 249,961 | 255,763 | ||
| Marketable debt securities | 22,067 | 51,454 | ||
| Intangible assets, net | 172,943 | 174,733 | ||
| Goodwill | 44,406 | 44,406 | ||
| Other assets | 57,862 | 60,121 | ||
| Total assets | 1,190,445 | 1,306,265 | ||
| Accounts payable | 40,573 | 34,242 | ||
| Accrued liabilities | 220,526 | 180,792 | ||
| Lease liabilities | 12,142 | 11,766 | ||
| Liabilities for sales of future royalties | 65,545 | 63,863 | ||
| Other liabilities | 1,236 | 2,581 | ||
| Total current liabilities | 340,022 | 293,244 | ||
| Lease liabilities | 21,691 | 24,531 | ||
| Deferred tax liabilities | 30,058 | 30,058 | ||
| Liabilities for sales of future royalties | 763,735 | 782,748 | ||
| Other liabilities | 18,780 | 17,398 | ||
| Total liabilities | 1,174,286 | 1,147,979 | ||
| Noncontrolling interest | 7,000 | 7,000 | ||
| Common stock, par value of 0.001 per share - 250,000,000 shares authorizedoutstanding - 96,442,027 in 2025 and 92,484,330 in 2024 | 96 | 96 | ||
| Treasury stock, at cost, 173,034 in 2025 and 69,757 in 2024 | 7,991 | 7,991 | ||
| Deferred compensation obligation | 7,991 | 7,991 | ||
| Additional paid-in capital | 4,411,531 | 4,374,333 | ||
| Accumulated other comprehensive income (loss) | 820 | -268 | ||
| Accumulated deficit | -4,403,288 | -4,222,875 | ||
| Total stockholders equity | 9,159 | 151,286 | ||
| Total liabilities, noncontrolling interest and stockholders' equity | 1,190,445 | 1,306,265 | ||
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)